- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05268289
Studie av effektivitet og sikkerhet av LNP023 hos deltakere med aktiv lupus nefritis klasse III-IV, +/- V
En adaptiv, randomisert, dobbeltblind, doseutforskning, parallell gruppe, placebokontrollert, multisenter fase 2-forsøk for å evaluere effektiviteten, sikkerheten og tolerabiliteten til LNP023 i kombinasjon med standardbehandling med og uten orale kortikosteroider hos pasienter med aktiv lupus Nefritt klasse III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Santa Fe, Argentina, S3000EPV
- Novartis Investigative Site
-
-
-
-
-
Salvador, Brasil, 40323-010
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil, 40150-150
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasil, 30150-221
- Novartis Investigative Site
-
Juiz de Fora, Minas Gerais, Brasil, 36010-570
- Novartis Investigative Site
-
-
São Paulo
-
Barretos, São Paulo, Brasil, 14784-400
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasil, 05403-000
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasil, 04038-002
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasil, 01308-050
- Novartis Investigative Site
-
-
-
-
-
Montería, Colombia, 230004
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080020
- Novartis Investigative Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombia, 111411
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Colombia, 680003
- Novartis Investigative Site
-
-
-
-
-
Quezon, Filippinene, 1102
- Novartis Investigative Site
-
-
National Capital Region
-
Makati City, National Capital Region, Filippinene, 1218
- Novartis Investigative Site
-
-
-
-
California
-
Los Angeles, California, Forente stater, 90095
- Ronald Reagan UCLA Medical Center
-
San Bernardino, California, Forente stater, 92408
- Loma Linda University
-
Sylmar, California, Forente stater, 91342
- Olive View UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- University of Colorado Denver
-
-
Florida
-
Hollywood, Florida, Forente stater, 33021
- Royal Research Corp
-
Orlando, Florida, Forente stater, 32806
- Nephrology Associates Of Central FL
-
Riverview, Florida, Forente stater, 33578
- Florida Kidney Physicians
-
-
Illinois
-
Hinsdale, Illinois, Forente stater, 60521
- Nep Assoc of Northern Illinois
-
-
Kansas
-
Wichita, Kansas, Forente stater, 67214
- Wichita Community Clcl Onco Program
-
-
Louisiana
-
New Orleans, Louisiana, Forente stater, 70121
- Ochsner Health System
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Johns Hopkins Hospital
-
-
New York
-
East Setauket, New York, Forente stater, 11733
- Stony Brook Internists PC
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19140
- Temple University
-
-
Texas
-
Dallas, Texas, Forente stater, 75204
- Dallas Nephrology Associates
-
Houston, Texas, Forente stater, 77054
- Prolato Clinical Research Center
-
-
-
-
-
Marseille, Frankrike, 13005
- Novartis Investigative Site
-
Nantes, Frankrike, 44093
- Novartis Investigative Site
-
-
-
-
Hong Kong
-
Hong Kong, Hong Kong, Hong Kong, 999077
- Novartis Investigative Site
-
-
-
-
Kerala
-
Kozhikode, Kerala, India, 673008
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, India, 110029
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad, Telangana, India, 500082
- Novartis Investigative Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, India, 226014
- Novartis Investigative Site
-
-
-
-
-
Beijing, Kina, 100034
- Novartis Investigative Site
-
Shenzhen, Kina, 518036
- Novartis Investigative Site
-
-
Guangxi
-
Nanning, Guangxi, Kina, 530022
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, Kina, 430022
- Novartis Investigative Site
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110004
- Novartis Investigative Site
-
-
Ningxia
-
Yinchuan, Ningxia, Kina, 750004
- Novartis Investigative Site
-
-
-
-
-
Selangor Darul Ehsan, Malaysia, 68100
- Novartis Investigative Site
-
-
Pahang
-
Kuantan, Pahang, Malaysia, 25100
- Novartis Investigative Site
-
-
Perak
-
Taiping, Perak, Malaysia, 34000
- Novartis Investigative Site
-
-
-
-
-
Aguascalientes, Mexico, 20230
- Novartis Investigative Site
-
Veracruz, Mexico, 91900
- Novartis Investigative Site
-
-
Tamaulipas
-
Tampico, Tamaulipas, Mexico, 89440
- Novartis Investigative Site
-
-
Yucatán
-
Mérida, Yucatán, Mexico, 97070
- Novartis Investigative Site
-
-
-
-
-
Carnaxide, Portugal, 2799-523
- Novartis Investigative Site
-
Coimbra, Portugal, 3004-561
- Novartis Investigative Site
-
Lisbon, Portugal, 1649-035
- Novartis Investigative Site
-
Vila Nova de Gaia, Portugal, 4434-502
- Novartis Investigative Site
-
-
-
-
-
San Juan, Puerto Rico, 00927
- FDI Clinical Research
-
-
-
-
Singapore
-
Singapore, Singapore, Singapore, 308433
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spania, 08036
- Novartis Investigative Site
-
Ciudad Real, Spania, 13005
- Novartis Investigative Site
-
Madrid, Spania, 28034
- Novartis Investigative Site
-
Madrid, Spania, 28040
- Novartis Investigative Site
-
Seville, Spania, 41009
- Novartis Investigative Site
-
-
-
-
-
Cambridge, Storbritannia, CB2 0QQ
- Novartis Investigative Site
-
-
-
-
Fatih
-
Istanbul, Fatih, Tyrkia (Türkiye), 34093
- Novartis Investigative Site
-
-
Melikgazi
-
Kayseri, Melikgazi, Tyrkia (Türkiye), 38039
- Novartis Investigative Site
-
-
Nilufer
-
Bursa, Nilufer, Tyrkia (Türkiye), 16059
- Novartis Investigative Site
-
-
Yenimahalle
-
Ankara, Yenimahalle, Tyrkia (Türkiye), 06500
- Novartis Investigative Site
-
-
Yenisehir
-
Mersin, Yenisehir, Tyrkia (Türkiye), 33110
- Novartis Investigative Site
-
-
-
-
-
Mainz, Tyskland, 55131
- Novartis Investigative Site
-
-
Lower Saxony
-
Braunschweig, Lower Saxony, Tyskland, 38126
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Tyskland, 51109
- Novartis Investigative Site
-
-
-
-
-
Budapest, Ungarn, 1083
- Novartis Investigative Site
-
Szeged, Ungarn, 6725
- Novartis Investigative Site
-
-
Hajdu Bihar Megye
-
Debrecen, Hajdu Bihar Megye, Ungarn, 4032
- Novartis Investigative Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Unequivocally positive ANA test result and/or a positive anti dsDNA at screening Active biopsy-proven lupus nephritis within 3 months of screening demonstrating Class III or IV lupus nephritis with or without co-existing features of Class V lupus nephritis.
Documentation of active renal disease at the time of screening necessitating the commencement of therapy with corticosteroids in combination with MMF/MPS.
eGFR ≥ 30 ml/min/1.73 m2 Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections Vaccination against Haemophilus influenzae infection Supportive care including stable dose regimen of anti-malarials (e.g. hydroxychloroquine) unless contraindicated, ACEi or ARB at either locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgement) at screening, as per the local clinical practice. Doses should remain stable throughout the study.
First presentation or flare of lupus nephritis.
Exclusion Criteria:
Induction treatment with cyclophosphamide within 3 months of planned treatment for this study; treatment with calcineurin inhibitors within the previous 3 months prior to randomization.
Presence of rapidly progressive glomerulonephritis (RPGN) as defined by 50% decline in eGFR within 3 months prior to screening.
Renal biopsy presenting with interstitial fibrosis/tubular atrophy (IF/TA) or glomerulosclerosis of more than 50%, or which in the opinion of the investigator is such that it precludes likely response to immunosuppressive therapy.
Participants being treated with systemic corticosteroids (>5 mg/day prednisone or equivalent) for indications other than SLE or LN e.g. acute asthma, inflammatory bowel disease.
Participants being treated with systemic corticosteroids for SLE or LN will be excluded if they have taken more than an average of 15 mg/day prednisone (or equivalent) in the previous 4 weeks and more than an average of 30 mg/day in the previous 1 week Receipt of more than a total dose of 1000 mg equivalent i.v. pulse methylprednisolone (cumulative dose) within 2 weeks prior to enrollment (and at enrollment)
Other protocol-defined inclusion/exclusion criteria may apply
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Iptacopan + standard of care (part 1)
Iptacopan + standard of care |
Taken for 52 Weeks
Andre navn:
|
|
Placebo komparator: Placebo matching iptacopan + standard of care (part 1)
Placebo matching iptacopan standard of care |
Taken for 52 Weeks |
|
Aktiv komparator: Iptacopan + standard of care (part 2)
Iptacopan + standard of care |
Taken for 52 Weeks
Andre navn:
|
|
Aktiv komparator: Iptacopan + placebo (part 2)
Iptacopan + placebo standard of care |
Taken for 52 Weeks
Andre navn:
|
|
Aktiv komparator: Placebo matching iptacopan + standard of care (part 2)
Placebo matching iptacopan + standard of care |
Taken for 52 Weeks |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Part 1 and 2: Proportion of patients achieving Complete Renal Response (CRR) at week 24 in the absence of renal flares
Tidsramme: Baseline and week 24
|
Part 1: To evaluate the proportion of patients achieving complete renal response with iptacopan treatment "A" plus standard of care, compared to treatment alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "B" plus standard of care, compared to treatment "D" alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "C" plus standard of care, compared to treatment "D" alone Complete Renal Response is defined as meeting the following criteria: estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m2 or no less than 85% of baseline value, and 24h urine protein-to-creatinine ratio (UPCR) ≤ 0.5 g/g. |
Baseline and week 24
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Parts 1 and 2: Proportion of patients achieving CRR or PRR in the absence of renal flares
Tidsramme: Baseline, week 24, week 52
|
Proportion of patients achieving complete renal response or partial renal response |
Baseline, week 24, week 52
|
|
Proportion of patients achieving ≥25% UPCR reduction in the absence of renal flares compared to baseline at week 24
Tidsramme: Baseline, week 24 week 52
|
Frequency of renal flares between weeks 24 and 52 |
Baseline, week 24 week 52
|
|
Log-transformed ratio to baseline of 24h UPCR at week 24
Tidsramme: Baseline week 24
|
Dose exposure response for reduction in proteinurea. (each 24h urine protein-to-creatinine ratio value will based on two 24 urine collections sampled within 10 days before the respective study visit) |
Baseline week 24
|
|
Change from baseline FACIT-Fatigue Score
Tidsramme: Weeks 24 and 52
|
Measure fatigue in patients |
Weeks 24 and 52
|
|
Change from baseline in SLEDAI-2K score at weeks 24 and 52
Tidsramme: Weeks 24 and 52
|
Measure disease activity in SLE |
Weeks 24 and 52
|
|
Change from baseline in BILAG-2004 score at weeks 24 and 52
Tidsramme: Weeks 24 and 52
|
Measure disease activity |
Weeks 24 and 52
|
|
Time-to-Complete Renal Response (CRR) based on first morning void(FMV) urine samples
Tidsramme: Week 24 and Week 52
|
Measurement of time to complete renal response based on urine samples |
Week 24 and Week 52
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Mannlige urogenitale sykdommer
- Nyresykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Bindevevssykdommer
- Autoimmune sykdommer
- Sykdommer i immunsystemet
- Vannlatingsforstyrrelser
- Urologiske manifestasjoner
- Glomerulonefritt
- Nefritt
- Patologiske tilstander, tegn og symptomer
- Hud- og bindevevssykdommer
- Tegn og symptomer
- Lupus erythematosus, systemisk
- Lupus nefritis
- Proteinuri
- Health Services Administration
- Helsevesenets kvalitet, tilgang og evaluering
- Kvalitet på helsehjelpen
- Kvalitetsindikatorer, helsehjelp
- Standard for omsorg
- Iptacopan
Andre studie-ID-numre
- CLNP023K12201
- 2021-002046-33 (EudraCT-nummer)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .